The upcoming patent expiry for Ozempic in India is set to dramatically lower the cost of semaglutide, making this once-premium diabetes and weight-loss drug accessible to more patients. This shift could reshape the market, prompting earlier prescriptions and potentially altering societal views on weight management and body acceptance.source https://timesofindia.indiatimes.com/india/when-cost-stops-being-the-barrier-the-new-chapter-of-ozempic-injection-in-india/articleshow/129201298.cms
0 Comments